The Innovative Therapies in Autoimmune Diseases Conference did not take place in 2011. The ACR plans to include the valuable content from this program in future educational offerings. If you have any questions regarding this meeting, please contact Valerie Okrend, Director, Continuing Medical Education at (404) 679-5305 or .
The Innovative Therapies in Autoimmune Diseases Conference is designed to provide an open forum for physicians, researchers and health professionals in clinical practice, academia, industry and regulatory agencies to address the development of new therapies for autoimmune diseases.
Collaboratively planned by representatives of the ACR, FDA and pharmaceutical/biotech organizations, this program will offer an overarching view of converging healthcare sectors and emerging therapeutic discoveries within the next decade. This program features thought leaders on topics such as vaccine development for the treatment of autoimmune diseases, innovative drug delivery systems, the impending availability of biosimilars and the regulatory pathways involved in their approval, advances in bioengineering and regenerative medicine, plus the changing climate of clinical trial design and execution with a hard look at economic and legal issues.
With thought provoking content and an interactive approach, attendees and speakers discuss new concepts and discoveries in science and technology and their potential for practical application, moving across a bidirectional pathway between scientific investigation and medical practice—from “bench to bedside” and back again.
Program
7:00 AM
Continental Breakfast
7:55 AM
Welcome
Eric Ruderman, MD • Northwestern University; Chicago, IL
SESSION I: Vaccines for Autoimmune Disease: Who, When and How
8:00 AM
Risk of Developing Autoimmune Disease: What Do We Need to Know Before We Can Intervene?
Hani S. El-Gabalawy, MD • University of Manitoba; Winnipeg, Manitoba, Canada
At the conclusion of this session participants should be able to:
- discuss genetic and environmental factors that contribute to the risk of RA development;
- review the strategies needed to develop a disease risk "score" for RA; and
- explore the potential design of a pre-clinical intervention in high risk individuals.
8:40 AM
Peptide Based Vaccines: Immunological and Clinical Effects of the DnaJ Peptide
Salvo Albani, MD, PhD •Sanford-Burnham Medical Research Institute; La Jolla, CA
At the conclusion of this session participants should be able to:
- explain the biological basis of a pre-clinical RA therapeutic intervention based on the DnaJ peptide;
- review the clinical experience with the DnaJ peptide in RA; and
- explore the design of an RA prevention trial using the DnaJ peptide.
9:20 AM
Cell Based Vaccines: How Do We Cross the Feasibility Barrier?
Eleanor N. Fish, PhD •Toronto General Research Institute; Toronto, Ontario, Canada
At the conclusion of this session participants should be able to:
- examine the potential role of T cells in the pre-clinical stages of autoimmune diseases such as RA and SLE;
- summarize the animal model data regarding use of T cell-based therapies in preventing autoimmune disease; and
- explore the design of clinical trials using T cell-based therapies in the prevention of RA and SLE.
10:00 AM
Break
SESSION II: Assessing Safety in the Post-Marketing Environment
10:30 AM
Analyzing Post-Marketing Databases to Assess Drug Safety: Pitfalls and Promises
Daniel H. Solomon, MD, MPH • Harvard Medical School; Boston, MA
At the conclusion of this session participants should be able to:
- explain the concept of data-mining of clinical databases;
- determine how appropriate interpretation of data from clinical databases can better inform clinical decision making; and
- acknowledge the limitations of reinterpreting data.
11:15 AM
Data Mining Post-Marketing Data: Using Propensity Scores to Level the Playing Field
Jeffrey Curtis, MD, MPH • The University of Alabama at Birmingham; Birmingham, AL
At the conclusion of this session participants should be able to:
- compare and contrast the value and limitations of post-marketing databases;
- interpret data from post-marketing databases to account for differences between enrolled subjects; and
- determine how data from post-marketing databases may have clinical practice application.
12:00 PM
Boxed Lunch
SESSION III: The Changing Environment for Innovation
1:00 PM
Promising Compounds – From Early State to Clinical Development: The Economic/Legal Perspective
Michael Heller, JD • Columbia Law School; New York, NY
At the conclusion of this session participants should be able to:
- discuss economic factors that may interfere with the development of new drugs; and
- explain the legal framework for drug development and its influence in the development of innovative products.
1:20 PM
Promising Compounds – From Early Stage to Clinical Development: The NIH Role in Facilitating Drug Development
Mark L. Rohrbaugh, PhD, JD • National Institutes of Health, Office of Technology Transfer; Rockville, MD
At the conclusion of this session participants should be able to:
- identify factors contributing to the "decline" in the development of new drugs; and
- clarify the role of NIH and its limitations in facilitating drug development.
1:40 PM
Promising Compounds – From Early Stage to Clinical Development: The Regulatory and Administrative Burden
Andrew C. Chan, MD, PhD • Genentech; South San Francisco, CA
At the conclusion of this session participants should be able to:
- describe the impact of regulatory agency requirements on the product development process; and
- explain industry's approach to regulatory challenges in the design and development of innovative products.
2:00 PM
Promising Compounds – From Early Stage to Clinical Development: FDA – Role for New Regulatory Authority
TBD
2:30 PM
Panel Discussion: Challenges to Innovation
Michael Heller,JD • Columbia Law School; New York, NY
Mark L. Rohrbaugh, PhD, JD • National Institutes of Health, Office of Technology Transfer; Rockville, MD
Andrew C. Chan, MD, PhD • Genentech; South San Francisco, CA
3:00 PM
Break
SESSION IV: Biosimilars
3:30 PM
Introduction to Biosimilars
Geoffrey Eich • Amgen, Inc.; Thousand Oaks, CA
At the conclusion of this session participants should be able to:
- differentiate between biosimilars and generic drug products;
- discuss the complexities of protein production; and
- describe the implications of a controlled process in protein production.
4:00 PM
European Medicines Agency Guidelines for Biosimilars
Andrea Laslop, MD • Austrian Agency for Health and Food Safety, PharmMed; Vienna, Austria
At the conclusion of this session participants should be able to:
- describe the general requirements for licensing a biosimilars product in Europe;
- explain the rationale behind biosimilars antibody guidance; and
- provide at least one positive and one negative example of the European experience with biosimilars.
4:30
Developing a Regulatory Pathway in the U.S.
Vibeke Strand, MD • Stanford University School of Medicine; Palo Alto, CA
At the conclusion of this session participants should be able to:
- interpret the proposed requirements for licensing a biosimilar in the US;
- discuss the implications for long-term safety monitoring; and
- review the requirements for claims around disease indication.
7:00 AM
Continental Breakfast
SESSION V: Innovative Delivery Systems
8:00 AM
Nanotechnology in Autoimmune Disease
Tarek Fahmy, PhD • Yale University; New Haven, CT
At the conclusion of this session participants should be able to:
- explain the integration of nanotechnology and biomaterials in the development of medical therapeutics;
- describe the current development in immunotherapeutic diagnostics, interventions and immune system cell response; and
- discuss the future of nanotechnology in the development of point-of-care diagnostics and personalized medicine.
8:30 AM
Bisphosphonates for Targeted Therapies
Reed Ayers, PhD • Colorado School of Mines; Boulder, CO
At the conclusion of this session participants should be able to:
- identify characteristics that make bisphosphonates useful tools for delivering therapeutic compounds directly to bone;
- discuss measures to enhance bioavailability of bisphosphonates and inhibit bone resorption; and
- discuss the future status of bisphosphonate-based drug delivery.
9:00 AM
Stapled Peptide Therapeutics
Speaker TBD
At the conclusion of this session participants should be able to:
- recognize stapled peptide elements that distinguish them from other protein-based therapeutics;
- acknowledge the unique strengths of stapled peptides as therapeutic compounds; and
- identify specific therapeutic targets that may be particularly amenable to the use of stapled peptides.
9:30 AM
Break
SESSION VI: New Directions
10:00 AM
Stem Cell Transplant in Scleroderma
Daniel Furst, MD • University of California, Los Angeles; Los Angeles, CA
At the conclusion of this session participants should be able to:
- discuss the biological basis for stem cell therapy in scleroderma;
- evaluate the trials of stem cell therapy in scleroderma; and
- identify patients appropriate for stem cell therapy trials.
10:15 AM
The Future of Gout
N. Lawrence Edwards, MD • University of Florida; Gainesville, FL
At the conclusion of this session participants should be able to:
- review recent progress in the understanding of renal transport of urate;
- discuss newer urate lowering therapy agents; and
- evaluate the latest treatment advances for gout and associated co-morbidities.
11:00 AM
Mesenchymal Stem Cells in Autoimmune Disease
Alan Tyndall, MD • University of Basel; Basel, Switzerland
At the conclusion of this session participants should be able to:
- define the biologic function of mesenchymal stem cells;
- identify sources of mesenchymal stem cells; and
- describe the therapeutic potential of mesenchymal cells in the treatment of autoimmune diseases.
11:30 AM
Mesenchymal Stem Cells in Articular Cartilage Repair
Speaker TBD
At the conclusion of this session participants should be able to:
- compare the use of MSCs for artricular cartilage repair to current available treatments;
- discuss the advantages and limitations of MSC-based cartilage repair strategies; and
- discuss the potential future of regenerative therapeutic options.
12:00 PM
Conclusion
+ Fees
- Fees
The registration fees are available until 12:00 midnight EST on the dates listed.
2011 Innovative Therapies in Autoimmune Diseases Conference |
|||
|---|---|---|---|
EARLY BIRD FEE |
REGISTRATION FEE |
ON-SITE FEE |
|
ACR/ARHP MEMBER |
$499 |
$585 |
$645 |
NON-MEMBER |
$715 |
$799 |
$879 |
ACR FIT MEMBER |
$189 |
$265 |
$295 |
NON-MEMBER FIT |
$305 |
$380 |
$420 |
RESIDENT / STUDENT |
$189 |
$265 |
$295 |
MASTER / EMERITUS |
$189 |
$265 |
$295 |
GUEST RECEPTION FEE |
$60 |
$60 |
$60 |
+ Register
- Register
Three Easy Ways to Register:
- Online
- Mail: Download the Innovative Therapies registration form
American College of Rheumatology
PO Box 102295, Atlanta, GA 30368, USA - Fax: Download the Innovative Therapies registration form
(404) 633-1870 (credit card payments only)
Need Help?
Contact the ACR for all your questions about your registration:
Monday–Friday, 9:00 AM – 5:00 PM ET
Phone: (404) 633-3777
E-mail:
Registration Confirmations
Attendees who pre-register by Monday, February 21, should receive a confirmation within seven business days. If you do not receive your confirmation, please call (404) 633-3777 or send notice via e-mail to: .
Registration Cancellations
All cancellations must be made in writing and received at the American College of Rheumatology 14 days prior to the meeting. Requests received after this date will not be honored. Cancellations are subject to a $50 processing fee and will be paid post-symposium.
+ Press
- Press
For a press registration form, contact Erin Latimer at or (404) 633-3777. All press registrations must be confirmed 10 days in advance of the meeting and will not be issued on-site.
Press passes are issued to individuals representing a recognized news organization, including freelancers who contribute to such organizations. To obtain a press badge, both photo identification, such as a driver’s license or passport, and identification certifying that you are a working member of the print, broadcast or online media are required. Such identification includes press credentials, or a business card and samples of your work. All freelancers must present a letter of assignment. Individuals who receive exhibitor passes are not eligible for press passes. The ACR has the right to inspect the credentials of anyone registering and reserves the right to refuse to register any individual as press.
Ineligible Registrants: The ACR does not issue press badges to: publishers or a publications’ advertising, marketing, public relations, sales, circulation, or any other non-editorial function representatives; industry/exhibitor press officers and their public relations consultants; financial or business analysts; educational program developers (including CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on ACR meeting content); trade media management personnel; or other individuals who are not actually reporting on the meeting.
Media who produce a communications vehicle that is sponsored by a single organization or whose revenue for the publication or issue of a publication depends solely on coverage of the ACR’s meeting also are ineligible to receive press credentials. In addition, media who produce communications vehicle that uses the ACR’s name or logo to imply endorsement from the ACR also are ineligible to receive press credentials. The ACR prohibits the development of CME content based on information presented at its meeting.
Be advised that based on space requirements, the ACR reserves the right to limit the number of press badges issued to a media organization. Typically, no more than two press passes will be issued to any one news organization.
+ Airline Reservations
- Airline Reservations
To make your airline or car rental reservations, contact ACR’s travel agency.
Association Travel Concepts
(800) 755-3899 or (858) 362-2719
Email:
Visit the ACR Travel Center at www.atcmeetings.com/ACR.
Book early to obtain the best travel options.
+ Ground Transportation
- Ground Transportation
Rates listed are subject to change.
Reagan National Airport
10 miles/5 minutes from Reagan National Airport
- Super Shuttle service is approximately $13 round-trip – call 1-800-BLUEVAN or go to www.supershuttle.com
- Taxi fare is approximately $10 - $12 one way plus a $2.50 airport fee
- Metro rail service (Blue and Yellow Lines) is available directly from the airport to the hotel (2 metro stops)
Click here for a map of the Washington DC metro system
Dulles International Airport
27 miles/30 minutes to from Dulles International Airport
Click here Washington Flyer Ground Transportation for all taxi and shuttle services available at Dulles Airport.
Taxi fare is approximately $57 – $61 one-way; Shuttle service is approximately $58 round trip
Washington DC Airports - Click here for information about Reagan National and Dulles International Airports.
Hotel Parking
Overnight valet parking is $29 per night; Day valet parking is $18 per day.
+ Accommodations
- Accommodations
To make housing reservations, contact the hotel directly and identify yourself as an attendee of the ACR Innovative Therapies in Autoimmune Diseases Conference. ACR reduced rates are subject to room availability through Friday, February 11, 2011. After this date, room rates cannot be guaranteed. Check with the hotel for any early departure fees and cancellation/refund policies.
Ritz-Carlton, Pentagon City
1250 South Hayes Street
Arlington, VA 22202
Phone: (800) 325-3535 or (703) 415-5000
Fax: (703) 415-5061
Website: The Ritz-Carlton, Pentagon City
Rate:
$149 single/double per night (standard rooms)
$20 charge per additional person
No charge for children under 18 years of age staying with parents
Tax:
Room rates are subject to city/state taxes. The current rate is 10.25% (tax rate is subject to change).
Direct Dial Reservations: Call the hotel directly at (800) 241-3333. Use the group code: RHE
Online Reservations: The Ritz-Carlton, Pentagon City – Use the special group code: RHERHEA
+ THINGS TO SEE AND DO
- THINGS TO SEE AND DO
Destination DC
901 7th Street NW, 4th Floor
Washington, DC 20001
Phone: (202) 789-7000
Website: www.washington.org
The Ritz-Carlton Hotel in Pentagon City is strategically located near the Crystal City and Rosslyn business districts, Old Town Alexandria, Capitol Hill and downtown Washington, DC. The hotel is just two metro stops from Reagan National Airport and downtown Washington, DC with easy access to all the monuments, museums, shopping and dining experiences that the Metro DC area has to offer.
Syllabus
To ensure that you have the most updated copy of each speaker’s presentation, syllabi will be available online following the course for registered attendees.
